The total genetic alteration frequency of NFE2L3 was 2.2% (244/10,950) in TCGA pan-cancer cohort, and the highest alteration frequency of NFE2L3 was approximately 6.4% in patients with UCEC. The gene discussed is NFE2L3; the disease is cancer.